drugset

drugset / Trial / NCT00863707

A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment

NCT00863707 ↗

Phase 4 Completed 511 enrolled Astellas Pharma Inc

RandomizedParallel-groupDouble-blindDiagnostic

Summary

This study is intended to assess the safety and tolerance of regadenoson in subjects with renal impairment.

Timeline

Start: 2009-04
Primary completion: 2009-12
Completion: 2009-12

Publications

Background Ananthasubramaniam K, Weiss R, McNutt B, Klauke B, Feaheny K, Bukofzer S. A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease. J Nucl Cardiol. 2012 Apr;19(2):319-29. doi: 10.1007/s12350-011-9508-3. Epub 2012 Jan 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Regadenoson	Diagnostic / imaging agent	0.4 mg	—

Indications